Update on MRI Biomarkers in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system, driven by immune-mediated myelin damage. Unlike neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease, which are diagnosed via serological testing, MS lacks biomarkers, relying on magnetic resonance imaging (MRI)-based spatial and temporal lesion dissemination per the 2017/2024 McDonald criteria. Perivenular lesions, a hallmark of MS, first described by James W. Dawson in 1916, are now visualized noninvasively using advanced MRI. Emerging biomarkers -central vein sign and paramagnetic rim lesions- demonstrate high specificity, improving diagnostic accuracy. Artificial intelligence innovations enhance biomarker detection and monitoring, enabling personalized therapies. This review highlights key MRI biomarkers, clinical interpretation, and recent advancements in MS diagnostics.